Boston Scientific Corp. (BSX) Monday received approval from the Food and Drug Administration for its Confient implantablecardioverter defibrillator, its Livian cardiac resynchronization therapydefibrillator and its upgraded Latitude patient management system.
All three products are part of the company's cardiac rhythm managementbusiness. Both the Confient and Livian defibrillators allow physicians to managetheir patients wirelessly on the Latitude patient management system.
Shares of the Natick, Mass.-based medical devices company closed Friday at$12.31.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment